I don’t know how many of you are in the stock market. (I know it’s a bad time for stocks) Anyway, I own some shares of a company named Therapeutic Solutions International. They are a super small biotech company that uses umbilical stem cells. Not the fetal stem cells from murdered babies. These are donated cord blood stem cells.

They have a COVID treatment that just got phase three approval. Their phase two results were nothing short of miraculous. The subjects were all end stage COVID patients and the rate of survival were 91% of patients over 85 and 100% under the age of 85.

They also have many other patents and a few products already on the market. I take one of them named Quadramune I haven’t had a sniffle since I started taking it along with my multi vitamin and vitamin D that I was taking already.

The company has a forum on their website, therapeuticsolutionsint.com where the CEO posts very often and even answers questions. Today the Chief Medical officer posted a great summary of their accomplishments. I will post it below. Sorry for the wall of text. I just believe in this company and think everyone should know about it. Also, F big pharma.

TSOI EXPANDING THE FRONTIERS OF STEM CELL TREATMENTS

by

James D. Veltmeyer, MD

Therapeutic Solutions International ( TSOI ), of which I serve as Chief Medical Officer, is opening new frontiers in the area of stem cell research which offers promising treatment for a variety of medical conditions, including COVID-19.

The political-financial-medical establishment is, of course, obsessed with vaccination as the solution to COVID. This makes sense in that vaccines are highly profitable to the pharmaceutical industry. Yet, everything we know about the COVID vaccines indicate – even from their most prominent cheerleaders – that they do not prevent infection or transmission of the virus, may be of limited efficacy in terms of duration, and spawn a host of serious side effects, including anaphylaxis, blood clots, myocarditis, paralysis, menstrual irregularities, neurological disorders, and Bell’s Palsy.

What we also know about COVID-19 is that it is generally highly treatable with a variety of drugs and therapeutics if caught in its early stages. This is true of many illnesses. For example, we have heard about hydroxychloroquine, ivermectin, regeneron, vitamin D and zinc being used widely to treat COVID patients, despite the relentless attacks made on these treatments by the Faucian wing of American politics and medicine.

What Therapeutic Solutions International is now exploring is the possibility of using JadiCell stem cell therapy to help COVID victims. This should be front-page news across the country. JadiCell is TSOI’s patented universal donor adult stem cell product. In clinical studies, JadiCell reduced pulmonary pathology in an animal model replicating the severe inflammation observed in patients infected with the Delta variant of COVID. JadiCell administration resulted in significant reduction of lung injury based on preservation of lung function, reduction of inflammatory cells entering the lung, and suppression of specific proteins such as C5a which are associated with poor prognosis in COVID-19 patients. In an FDA double-blind placebo-controlled clinical trial, the JadiCell was successful at substantially improving survival in end-stage patients with COVID-19 associated acute lung failure. Specifically, treatment was associated with significantly improved patient survival ( 91% versus 42% ) of individuals over the age of 85. JadiCell was actually shown to be 100% effective in saving the lives of COVID patients under the age of 85.

Recently, TSOI received clearance from the FDA to initiate a Phase III pivotal trial for registration of JadiCell as a treatment for COVID-19 associated lung failure. JadiCell has shown itself to be superior to other types of stem cells, including bone marrow, adipose, cord blood, and placenta. No other cells have demonstrated this unprecedented ability to both suppress inflammation while restoring the function of tissue damaged by the virus.

In addition, TSOI’s research is indicating the superior ability of JadiCell in stimulating production of new brain cells. This process is called “neurogenesis” and has great potential in the fight against Alzheimer’s Disease, Parkinson’s Disease, and various forms of dementia.

TSOI possesses the only filed Investigational New Drug ( IND ) application for treatment of chronic traumatic encephalopathy ( CTE ). CTE is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players and other athletes. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe.

It is worth noting that while our establishment politicians and medicrats remain focused exclusively on vaccines and vaccination as the way to combat disease, many scientists and researchers – such as those at Therapeutic Solutions International – continue to toil away day after day – almost unnoticed and unappreciated by the general public – in their quest to find actual cures for disease, not just for COVID but for a host of others that continue to plague and pester mankind. It is time that these modern-day Curies are recognized and applauded for their courageous and groundbreaking work that offers to save the lives of millions of people in coming years.

Dr. James Veltmeyer is a prominent La Jolla physician and author of “Physician on a Mission: Dr. Veltmeyer’s RX to Save America.”He was voted "Top Doctor" in San Diego County in 2012, 2014, 2016, 2017, and 2019. Dr. Veltmeyer can be reached at [email protected] and by visiting his website at drveltmeyer.com

4150 Regents Park Row, Suite 321 La Jolla, CA 92037